Abstract: OBJECTIVE To evaluate the risk of post-finasteride syndrome(PFS) induced by finasteride, in order to provide more evidence for clinical rational and safe drug use. METHODS All data related to finasteride from the fourth quarter of 2015 to the second quarter of 2021 were extracted from FAERS database. Reporting odds ratio(ROR) method was used to data mining on the risk of PFS induced by finasteride. Furthermore, subgroup analyses were conducted by dosage, age and diagnosis. The effect of different finasteride dosages on the clinical outcome of PFS was investigated. RESULTS The results observed the risk signal of finasteride-related PFS(ROR 18.69; 95%CI 17.05-20.49). Sexual dysfunction signals for 1 mg finasteride group and diagnosis of androgenic alopecia group were stronger than others (ROR 889.61; 95%CI 746.94-1 059.52) and (ROR 729.58; 95%CI 629.09-846.14), respectively. Patients at the age range of 18 to 44 were more likely to have PFS. The outcome of PFS induced by different finasteride dosage had statistical significance(P<0.05). The serious outcome rate of PFS was high by a disability rate of 19.07%, hospitalization rate of 14.53% and death rate of 7.07%. CONCLUSION Finasteride can induce PFS with high incidence of serious adverse reactions. The public and clinicians should pay great attention and distinguish the adverse reactions caused by finasteride, so as to ensure the drug safety for patients.